Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

被引：13

作者：

Zaja, Francesco ^{[1
,2
]}

Salvi, Flavia ^{[3
]}

Rossi, Maura ^{[4
]}

Sabattini, Elena ^{[5
]}

Evangelista, Andrea ^{[5
]}

Ciccone, Giovannino ^{[6
,7
]}

Angelucci, Emanuele ^{[8
]}

Gaidano, Gianluca ^{[9
]}

Zanni, Manuela ^{[9
]}

Ladetto, Marco ^{[3
]}

Chiappella, Annalisa ^{[10
]}

Vitolo, Umberto ^{[10
]}

Zinzani, Pier Luigi ^{[11
]}

Califano, Catello ^{[12
]}

Tucci, Alessandra ^{[13
,14
]}

Patti, Caterina ^{[15
]}

Pileri, Stefano A. ^{[16
]}

Lenti, Valentina ^{[17
]}

Piccaluga, Pier Paolo ^{[4
]}

Cavallo, Federica ^{[18
]}

Volpetti, Stefano ^{[19
,20
]}

Perali, Giulia ^{[19
,20
]}

Assouline, Sarit ^{[21
]}

Mann, Koren Kathleen ^{[22
]}

Morin, Ryan ^{[23
]}

Alcaide, Miguel ^{[23
]}

Bushell, Kevin ^{[23
]}

Fanin, Renato ^{[1
,2
]}

Levis, Alessandro ^{[17
]}

机构：

[1] Univ Udine, Clin Ematol, DAME, Udine, Italy

[2] Univ Udine, Unita Terapie Cellulari Carlo Melzi, DAME, Udine, Italy

[3] AO SS Antonio & Biagio & C Arrigo, SC Ematol, Alessandria, Italy

[4] Univ Hosp Bologna, Unit Haemolymphopathol, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[5] Univ Hosp Bologna, Dept Hematol & Oncol, Unit Haemolymphopathol, Bologna, Italy

[6] AOU Citta Salute & Sci Torino, Unit Clin Epidemiol, Turin, Italy

[7] CPO Piemonte, Turin, Italy

[8] IRCCS AOU San Martino IST, UOC Ematol, Genoa, Italy

[9] Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, Novara, Italy

[10] AOU Citta Salute & Sci, SC Ematol, Turin, Italy

[11] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy

[12] Osped Umberto I, UO Med Oncoematol, Nocera Inferiore, Italy

[13] Spedali Civil Brescia, SC Ematol, Brescia, Italy

[14] Spedali Civil Brescia, Dipartimento Oncol Med, Brescia, Italy

[15] Osped V Cervello, UOC Ematol, Palermo, Italy

[16] Milano Univ, Sch Med, European Inst Oncol, Haematopathol Unit, Bologna, Italy

[17] Fdn Italiana Linfomi, Alessandria, Italy

[18] Univ Torino, Azienda Osped Univ Citta Salute & Sci, Turin, Italy

[19] Azienda Sanit Univ Integrata, Clin Ematol, Udine, Italy

[20] Azienda Sanit Univ Integrata, Unita Terapie Cellulari Carlo Melzi, Udine, Italy

[21] McGill Univ, Jewish Gen Hosp, Div Hematol, Montreal, PQ, Canada

[22] McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada

[23] Simon Fraser Univ, Dept Mol Biol & Biochem, Sch Comp Sci, Vancouver, BC, Canada

来源：

LEUKEMIA & LYMPHOMA | 2018年 / 59卷 / 12期

关键词：

Diffuse large B-cell lymphoma; panobinostat; relapsed/refractory; genomic; DEACETYLASE INHIBITOR PANOBINOSTAT; HISTONE DEACETYLASES; RITUXIMAB; DISEASE; MULTICENTER; ROMIDEPSIN; MUTATION; LBH589; TRIAL; CHOP;

D O I：

10.1080/10428194.2018.1452208

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1% and 11.4%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26%, 11% and 11%, respectively. Four patients who achieved a sustained CR, continued receiving panobinostat for an overall period of 44, 48, 50, 62 months. Thrombocytopenia grade 3 (5 patients) and 4 (24 patients) represented the main toxic effect, causing dose reduction or treatment suspension in 19 patients. Genomic analysis was unable to identify any relationship between mutations and response; TP53 mutation appeared not to impact the clinical outcome. Overall, panobinostat has a modest activity in R/R DLBCL patients, however it can induce very long lasting responses in some cases. Thrombocytopenia frequently limits the use of this agent.

引用

页码：2904 / 2910

页数：7

共 50 条

[31] Glofitamab in Relapsed Refractory Diffuse Large B-Cell Lymphoma: Single Center Experience
Yaman, Samet
Candir, Burcu Aslan
Bozan, Ersin
Dal, Mehmet Sinan
Altuntas, Fevzi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S445 - S445
[32] Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma
Umino, Kento
Fujiwara, Shin-Ichiro
Ikeda, Takashi
Kawaguchi, Shin-Ichiro
Toda, Yumiko
Ito, Shoko
Ochi, Shin-Ichi
Nagayama, Takashi
Mashima, Kiyomi
Minakata, Daisuke
Nakano, Hirofumi
Yamasaki, Ryoko
Morita, Kaoru
Kawasaki, Yasufumi
Yamamoto, Chihiro
Ashizawa, Masahiro
Hatano, Kaoru
Sato, Kazuya
Oh, Lekuni
Ohmine, Ken
Muroi, Kazuo
Kanda, Yoshinobu
LEUKEMIA & LYMPHOMA, 2019, 60 (08) : 1926 - 1933
[33] RISK ASSESSMENT AND MANAGEMENT OF CNS INVOLVEMENT IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN ITALIAN CENTERS: A NATIONWIDE SURVEY BY THE FONDAZIONE ITALIANA LINFOMI (FIL)
Gini, G.
Di Rocco, A.
Sampaolo, M.
Nassi, L.
Arcari, A.
Tisi, M. C.
Loseto, G.
Gentile, M.
Annibali, O.
Ferreri, A. J. M.
Balzarotti, M.
HAEMATOLOGICA, 2019, 104 : 62 - 63
[34] A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Crombie, Jennifer L.
Kim, Austin I.
Bartlett, Nancy L.
Redd, Robert A.
Patterson, Victoria
Carey, Celeste
Balasubramanian, Sobana
Odejide, Oreofe O.
Merryman, Reid W.
LaCasce, Ann
Jacobson, Caron A.
Jacobsen, Eric
Parry, Erin M.
Fisher, David C.
Herrera, Alex F.
Davids, Matthew S.
Shipp, Margaret A.
Armand, Philippe
Shouse, Geoffrey P.
BLOOD, 2023, 142
[35] BRENTUXIMAB VEDOTIN IN THE TREATMENT OF RELAPSED/REFRACTORY CD30 POSITIVE PERIPHERAL T-CELL LYMPHOMA PATIENTS: A PHASE 2 STUDY OF THE FONDAZIONE ITALIANA LINFOMI
Carella, M.
Pellegrini, C.
Corradini, P.
Orsucci, L.
Volpetti, S.
Argnani, L.
Dodero, A.
Stefoni, V.
Zinzani, P. L.
HAEMATOLOGICA, 2021, 106 (10) : 70 - 70
[36] Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma
Georg Lenz
Eliza Hawkes
Gregor Verhoef
Corinne Haioun
Soon Thye Lim
Dae Seog Heo
Kirit Ardeshna
Geoffrey Chong
Jacob Haaber
Wei Shi
Igor Gorbatchevsky
Susanne Lippert
Florian Hiemeyer
Paolo Piraino
Georg Beckmann
Carol Peña
Viktoriya Buvaylo
Barrett H. Childs
Gilles Salles
Leukemia, 2020, 34 : 2184 - 2197
[37] Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma
Lenz, Georg
Hawkes, Eliza
Verhoef, Gregor
Haioun, Corinne
Thye Lim, Soon
Seog Heo, Dae
Ardeshna, Kirit
Chong, Geoffrey
Haaber, Jacob
Shi, Wei
Gorbatchevsky, Igor
Lippert, Susanne
Hiemeyer, Florian
Piraino, Paolo
Beckmann, Georg
Pena, Carol
Buvaylo, Viktoriya
Childs, Barrett H.
Salles, Gilles
LEUKEMIA, 2020, 34 (08) : 2184 - 2197
[38] Late Cardiological Sequelae and Long-Term Monitoring in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi
Oliva, Stefano
Puzzovivo, Agata
Gerardi, Chiara
Allocati, Eleonora
De Sanctis, Vitaliana
Minoia, Carla
Skrypets, Tetiana
Guarini, Attilio
Gini, Guido
CANCERS, 2022, 14 (01)
[39] A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Collins, Graham P.
Toby, Eyre A.
Hatton, Chris S.
Radford, John
Linton, Kim M.
BLOOD, 2014, 124 (21)
[40] LATE TOXICITIES AND LONG-TERM MONITORING IN CLASSICAL HODGKIN LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA SURVIVORS: A SERIES OF SYSTEMATIC REVIEWS OF THE FONDAZIONE ITALIANA LINFOMI
Minoia, C.
Gerardi, C.
Allocati, E.
De Sanctis, V.
Franceschetti, S.
Viviani, S.
Annunziata, M. A.
Bari, A.
Skrypets, T.
Oliva, S.
Puzzovivo, A.
Di Molfetta, S.
Caccavari, V.
Di Russo, A.
Loseto, G.
Daniele, A.
Nassi, L.
Gini, G.
Guarini, A.
HAEMATOLOGICA, 2021, 106 (10) : 170 - 170

← 1 2 3 4 5 →